This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Is Being Unethical Worth It?: Opinion

Stocks in this article: BCS GSK PFE JPM

NEW YORK ( TheStreet) -- Within the last few days of writing this commentary, and prior to celebrating our July Fourth independence, two significant scandals have been resolved, one in the banking industry and another in pharmaceuticals.

GlaxoSmithKline (GSK) agreed to plead guilty to misdemeanor criminal charges and pay $3 billion to settle what government officials described as the largest case of health care fraud in U.S. history.

GSK targeted the antidepressant Paxil to under-age patients, pushed Wellbutrin for uses it was not approved for, falsified articles, used illegal kickbacks, and also failed to give the U.S. Food and Drug Administration safety data about its diabetes drug Avandia.

Barclays PLC (BCS), the huge international banking concern of the U.K., has agreed to pay $453 million in fines to the U.S. Justice Department and the U.K.'s Financial Services Authority over charges it manipulated the LIBOR, a short-term interest rate used to calculate consumer bank loans, from mortgages to credit cards.

Barclays Chief Executive Bob Diamond Stepping Down
They're very different and yet identical. Why?

Different incidents and different industries. Yet the reasons are the same: Both U.K.-based giants had someone(s) at the top who made very bad decisions, and influenced enough subordinates to support turning an exception to policy and practice into the rule. This is not what is meant by exceptional leadership.

What's going to come of these two companies?

  • Their stock values will be diminished in the near term.
  • There will be announcements of major policy, process and practice improvements prior to the year's end.
  • However, neither company will go away. They are both icons with substantial assets to endure the latest penalties, downturn in business and reputation dips.
What's going to come of these two industries?
  • Banking and big pharma take another self-induced hit of scandalous practices. In 2009, Pfizer (PFE) was hit with a $2.3 billion settlement for improperly marketing 13 drugs. Barclays' upset comes only months after the $2 billion+ debacle with JPMorgan Chase (JPM) investment-risk meltdown.
  • Regulatory and investigative attention will increase.
  • Advertising, public relations campaigns, legal fees, risk-management efforts and training budgets will go through the roof.
What's going to come of leaders performing badly in general?
  • There may be leadership shake-ups and board shuffling and those who stand accused will move on to other companies.

What should happen?

Leaders directly responsible for the activities should be held accountable:

  • They should be immediately fired or removed;
  • granted no resignation severance packages or benefits;
  • all compensation gained during the illicit practices should be clawed back and used to partially pay for the settlements;
  • they should be banned from holding any executive role in their particular industry for up to 10 years;
  • should not be allowed to leverage their misconduct into any means of profiteering such as lectures, books, media interviews, consulting, etc.;
  • company board members should also be immediately removed and undergo the aforementioned punishments including their inability to serve on any other corporate boards for up to 10 years.

Sounds a bit harsh. It should.

Until business in general and industries in particular make the consequences of misconduct harsh, others will continue to find quick ways to make a buck, regardless of how many fiscal and literal lives are put in jeopardy.

One bit of "silver lining to this cloud" is that GSK plead "guilty" as opposed to the proverbial, common U.S. company weasel legalese that "this settlement in no way is an admission of guilt." To that, maybe we can say GSK gets it. Time will tell.

Industry, investors and consumers will all be watching the next step(s) to regaining trust and value in both Big Pharma and Big Banking.

This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,625.95 +269.08 1.55%
S&P 500 2,043.88 +30.99 1.54%
NASDAQ 4,718.6120 +74.30 1.60%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs